Release Summary. Log in sign up. In addition, we were prepared to initiate the Phase 1 portion of a Phase 1/2 clinical trial in March; however, the COVID-19 pandemic required us to temporarily delay initiating that trial and adjust some other timelines. BELTSVILLE, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Based on the current enrollment criteria and clinical response data, at this time the company does not plan to advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts into the stage 2 portion of the Simon 2-stage trial. This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
9000 Virginia Manor Road | Suite 200 | Beltsville, MD 20705 | USA | (240) 399-4900 Examples of forward-looking statements in this press release include, among others, statements about NextCure’s ongoing clinical study of NC410, NextCure… NextCure assumes no obligation to update any forward-looking statements. The company will evaluate whether to pursue additional monotherapy studies in NSCLC and ovarian cancer after a review of that information. LAIR-2 is a naturally occurring soluble version of LAIR-1, which binds to and blocks the inhibitory activity of LAIR-1 and thus acts as a decoy protein. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure … BELTSVILLE, Md., July 07, 2020 (GLOBE NEWSWIRE) -- The Phase 1 dose-escalation portion of this open-label trial is designed to evaluate the safety and tolerability of NC410 in patients with advanced or metastatic solid tumors and determine its pharmacologically active and/or maximum tolerated dose. Press Release reported on 07/15/20 that Scott+Scott Attorneys at Law LLP Announces Investigation into NextCure, Inc. (NXTC) >> Stay Up To Date On The Best Stocks Under $5 + Market Moving Updates 100% Free. The analysis of biomarker data for these cohorts has been delayed and is not yet complete. After a recommended dose for the Phase 2 portion of the trial is determined, the efficacy of NC410 will be evaluated in select tumor types.“We are pleased to initiate this first clinical trial of NC410, our second product candidate to reach the clinic, after a brief delay announced in April as a result of the COVID-19 pandemic. This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. User account menu.
The company is continuing to assess Siglec-15 (S15) biomarker data as a basis for patient selection.“While the monotherapy data in the NSCLC and ovarian cancer cohorts are disappointing, we continue to evaluate patient selection criteria for our ongoing NC318 clinical trials,” said “We thank Kevin for all of his work on behalf of the company and look forward to his continued support as a clinical consultant,” said NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer ET Press Release reported on 07/15/20 that Scott+Scott Attorneys at Law LLP Announces Investigation into NextCure, Inc. (NXTC) >> Stay Up To Date On The Best Stocks Under $5 + Market Moving Updates 100% Free. Press question mark to learn the rest of the keyboard shortcuts. The company will evaluate whether to pursue additional monotherapy studies in NSCLC and ovarian cancer after a review of that information. 1. NextCure (NASDAQ:NXTC): FY GAAP EPS of -$2.15 misses by $0.12.Revenue of $6.35M beats by $0.46M.Press Release This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform … These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Posted by 4 hours ago. Press J to jump to the feed.